Glaxo Sees Hope for Respiratory Drugs as Earnings Beat Estimates

GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled the start of a turnaround in its troubled respiratory medicine business as the company reported fourth-quarter earnings that beat analyst estimates.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.